Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

@inproceedings{Huang2017SustainedIO,
  title={Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial},
  author={Li-Min Huang and Thanyawee Puthanakit and Chiu Cheng-Hsun and Tang Ren-Bin and Tino F Schwarz and Angelo Pellegrino and Susanna Esposito and Louise Frenette and Shelly A McNeil and Paolo Durando and Paul Rheault and Carlo Giaquinto and Matthias Horn and K U Petry and Klaus Peters and Toma Azhar and Peter Hillemanns and St{\'e}phanie De Simoni and Damien Friel and Suryakiran Pemmaraju and Marjan Hezareh and Florence Thomas and Dominique Descamps and Nicolas Folschweiller and Frank Struyf},
  booktitle={The Journal of infectious diseases},
  year={2017}
}
Background We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]). Methods Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

on HPV and Cancer

ICO Information Centr
  • Human Papillomavirus and Related Diseases Report–World. http://hpvcentre.net/statistics/reports/XWX.pdf. Accessed April 10
  • 2016
VIEW 1 EXCERPT